Strongbridge Biopharma plc
SBBP · NASDAQ
12/31/2020 | 12/31/2019 | 12/31/2018 | 12/31/2017 | |
|---|---|---|---|---|
| Revenue | $31 | $22 | $18 | $7 |
| % Growth | 41.5% | 20.4% | 155.8% | – |
| Cost of Goods Sold | $2 | $4 | $4 | $1 |
| Gross Profit | $29 | $18 | $14 | $6 |
| % Margin | 92.8% | 82.4% | 77.9% | 79% |
| R&D Expenses | $26 | $31 | $25 | $17 |
| G&A Expenses | $41 | $46 | $63 | $36 |
| SG&A Expenses | $41 | $46 | $63 | $36 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $5 | $5 | $7 | $5 |
| Operating Expenses | $72 | $82 | $96 | $59 |
| Operating Income | -$43 | -$64 | -$82 | -$53 |
| % Margin | -140.5% | -294.1% | -454.4% | -752.5% |
| Other Income/Exp. Net | -$2 | $16 | $114 | -$59 |
| Pre-Tax Income | -$45 | -$48 | $32 | -$112 |
| Tax Expense | -$0 | $2 | $1 | $2 |
| Net Income | -$45 | -$49 | $32 | -$113 |
| % Margin | -146.7% | -227.8% | 176.7% | -1,610.6% |
| EPS | -0.8 | -0.89 | 0.64 | -3.11 |
| % Growth | 10.1% | -239.1% | 120.6% | – |
| EPS Diluted | -0.8 | -0.89 | 0.64 | -3.11 |
| Weighted Avg Shares Out | 56 | 55 | 50 | 37 |
| Weighted Avg Shares Out Dil | 56 | 55 | 50 | 37 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $1 | $0 | $13 | $4 |
| Depreciation & Amortization | $5 | $5 | $7 | $5 |
| EBITDA | -$39 | -$43 | $52 | -$102 |
| % Margin | -125.8% | -196.1% | 289.2% | -1,452.8% |